NKGen Biotech, Inc.

NKGen Biotech, Inc., trading under the ticker GFOR on Nasdaq, is a clinical-stage biopharmaceutical company that completed its merger with Graf Acquisition Corp. IV, a blank-check vehicle sponsored by Graf & Company, in 2023. The SPAC originally went public in 2022 targeting the healthcare and life sciences sector, with NKGen Biotech focused on developing natural killer cell-based therapies for oncology and neurodegenerative indications. The company filed an 8-K with the SEC on September 9, 2025, continuing its post-merger disclosure obligations as a public entity. For the full filing history, deal timeline, and post-merger data on GFOR, sign up for complete access at SpacDesk.